SCYX - Scynexis stock rises as Brexafemme sales nearly double Q/Q

• Scynexis ( NASDAQ: SCYX ) stock rose ~3% on Aug. 15 after Q2 revenue grew 29% Q/Q.
• Sales of vaginal yeast infection drug Brexafemme (ibrexafungerp tablets) increased to $1.3M in Q2, compared to $0.7M in Q1.
• "We are pleased to see the improvements to the current sales trajectory, and we are well capitalized with a cash runway into the first quarter of 2024 to execute on the next important steps toward our goal of building a broad, long-lasting antifungal franchise," said Scynexis President and CEO Marco Taglietti.
• As of June 30, cash and cash equivalents were $118.7M, compared to $104.5M on Dec. 31, 2021.
• Scynexis noted that it expects FDA to make a decision on its application seeking expanded approval of Brexafemme for preventing recurrent vulvovaginal candidiasis (VVC) by Nov. 30.
• Q2 net loss widened to -$13.3M, compared to a net gain of $1.7M in Q2 2021.
• Outlook :
• "For the remainder of the year we will be focused on preparing for the approval of the recurrent VVC indication, while working to enroll invasive candidiasis patients into our MARIO study," commented Taglietti.

For further details see: